The multicohort, phase 1 KEYNOTE-028 study in patients with PD-L1-positive NET treated with pembrolizumab demonstrated an ORR of 12.0% in patients with carcinoid and 6.3% in patients with well-differentiated or moderately-differentiated pancreatic NET (7). The gene discussed is CD274; the disease is pancreatic neuroendocrine tumor.